Janus Henderson Group PLC Acquires 264,833 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Janus Henderson Group PLC lifted its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 5.2% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,354,981 shares of the company’s stock after buying an additional 264,833 shares during the period. Janus Henderson Group PLC owned about 0.08% of Structure Therapeutics worth $258,260,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of GPCR. Morgan Stanley boosted its stake in Structure Therapeutics by 261.4% in the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after buying an additional 1,510,093 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Structure Therapeutics by 25.2% during the fourth quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock worth $495,334,000 after buying an additional 1,432,797 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Structure Therapeutics by 477.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock valued at $116,228,000 after purchasing an additional 1,381,745 shares during the last quarter. Avoro Capital Advisors LLC boosted its position in Structure Therapeutics by 21.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock worth $455,939,000 after buying an additional 1,150,000 shares during the period. Finally, Capitolis Liquid Global Markets LLC acquired a new position in shares of Structure Therapeutics during the fourth quarter worth $61,086,000. 91.78% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on GPCR. HC Wainwright reduced their target price on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, June 11th. Wall Street Zen cut Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Canaccord Genuity Group started coverage on shares of Structure Therapeutics in a research report on Monday, April 27th. They set a “buy” rating and a $101.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $110.55.

Structure Therapeutics Price Performance

Shares of GPCR opened at $49.47 on Friday. The firm has a market cap of $3.52 billion, a PE ratio of -56.86 and a beta of -1.50. Structure Therapeutics Inc. Sponsored ADR has a 1 year low of $15.80 and a 1 year high of $94.90. The stock’s fifty day moving average price is $46.33 and its two-hundred day moving average price is $55.30.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. Sell-side analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current fiscal year.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.